Discover
GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Teclistamab, Talquetamab, and Elranatamab: Response Rates and Data

Teclistamab, Talquetamab, and Elranatamab: Response Rates and Data
Update: 2024-05-10
Share
Description
Dr. Sridevi Rajeeve discusses the unprecedented response rates in patients treated with teclistamab, talquetamab, and elranatamab, as well as their clinical trial data.
Comments
In Channel